The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
about
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasmsReview article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China.Stochastic dynamics and the evolution of mutations in stem cellsRuxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the legInfluence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders.JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.Adrenal incidentaloma and the Janus Kinase 2 V617F mutation: A case-based review of the literature.Nuclear JAK2: form and function in cancer.Inherited predisposition to myeloproliferative neoplasmsThe JAK-STAT pathway: impact on human disease and therapeutic interventionOccurrence of the JAK2 V617F mutation in patients with peripheral arterial disease.Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.Ethical considerations in genomic testing for hematologic disorders.Dynamics of mutant cells in hierarchical organized tissues.JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer developmentMolecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.Focal 18F-FDG uptake in bone marrow on PET/CT in a patient with JAK2 mutation without overt myeloproliferative neoplasm.Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation.Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.Characterization of blood donors with high haemoglobin concentration.Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis.Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis.Q57652741Chronic Lymphocytic Leukemia and Myelofibrosis
P2860
Q28392728-ADBFE813-8A3F-4CBA-BBBC-968EAB8641FFQ30244631-C693AA6F-393D-44BF-83C4-7FE1247D590FQ31017219-ED1BB84A-11C7-4EC0-A4BD-4BBFBFFC49DBQ33422507-0CF498F0-D3B0-4BDD-9A4C-9F7D9F492E0CQ34375134-FACE848D-2722-4F67-BEEA-257E18C8FEB9Q35643476-692C314D-08E4-4A33-84AC-A4B8C272D92FQ35834175-2B71160F-8395-4EE2-9AFB-E17BA93DB47BQ36036299-58006DA3-DCA8-4C10-82DD-490C490B0C70Q36862199-59823D92-19C2-45D5-BF45-011289844182Q37910092-F9F52E21-943D-4AEE-9EE2-B903EC5FDD0DQ38127417-12A379CF-F195-4504-BFE7-3F42D62A9016Q38317993-4925766F-AEC1-4635-A461-CA4BB39EC595Q39108026-0CF3074C-576B-41A9-B47F-9017400D6252Q39309957-40754F1A-DC77-4565-B341-B897A489CA3AQ39363424-E6F2E7C5-22B7-47EB-93E6-B08E8247EA05Q39535374-BE3FFEF2-C0FE-44A7-981C-096D738723E1Q41499758-6CF2CFD2-6F6D-4FC8-8E4B-88F11C4FE4A2Q41576528-4C75C45D-6443-48A0-9DE6-34EB28B4CD55Q43979129-D6DC9BB5-D804-4A8A-BCEE-53A4435DC5D2Q44345261-02420607-683F-4F86-ABA1-6DCF0202A784Q46012544-2F1933D3-4DDA-49E6-80D2-4B790B011204Q46886345-4D122B93-9F82-4C69-9545-1FA04A41C4DDQ49324407-BB005D37-42B9-4AA9-BB7F-A4092D1E7814Q49834761-71F2E297-C2DF-4952-A577-F2C3D79E8440Q51333593-7394CE0E-F403-41C2-A949-EB39DB750235Q51354558-3EC18A84-4921-44D2-B409-0A9C69EC87B7Q53680800-3BBFF6E7-3B47-4D17-86C1-2E9EB83325FEQ55071902-65DDD4CF-FF34-468F-8FBE-621E37FFED9BQ57652741-C9371AB0-1228-4CCF-AAA7-8B31059CC3DFQ58795213-4F068858-414F-45E1-A822-CCE1054A1643
P2860
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
@ast
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
@en
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
@nl
type
label
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
@ast
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
@en
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
@nl
prefLabel
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
@ast
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
@en
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
@nl
P2093
P2860
P1433
P1476
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
@en
P2093
Camilla Nielsen
Henrik S Birgens
Lasse Kjaer
P2860
P304
P356
10.3324/HAEMATOL.2010.033191
P577
2010-12-15T00:00:00Z